Prof. Elgebaly founded Nour Heart, Inc. in 2006 to pursue research into heart-related diagnostic and therapeutic products and is a Professor at the University of Connecticut Faculty of Medicine (Adj.), Farmington, Connecticut, U.S.

The U.S. Food and Drug Administration (FDA) has recently granted Orphan Drug Designation to Nour Heart's new drug Cyclocreatine Phosphate for the prevention of ischemic injury to enhance cardiac graft recovery and survival in heart transplantation (DRU-2015-4951).



Dr. Salwa Ahmed Elgebaly of Nour Heart Inc. to be Featured on CUTV News Radio

VIENNA, VIRGINIA, UNITED STATES, January 27, 2020 /EINPresswire.com/ -- There are 250,000 people with end-stage heart failure who could qualify for a heart transplant, but only 2,500-3,000 transplants are performed each year.
There have been few innovations that could actively expand the donor pool, but a new drug could change the scope of heart transplantation for years to come.
Dr. Salwa A. Elgebaly, PhD is the Founder and CEO of Nour Heart, Inc., dedicated to the development of the new cardioprotective drug, Cyclocreatine Phosphate for patients with Ischemic Heart Diseases.
“I wanted to bring this to life for the people whose stories touched me,” says Dr. Elgebaly. “I believe in Cyclocreatine phosphate.”


Press Release Nov. 2019


Prof. Salwa A. Elgebaly Celebrated for Dedication to the Field of Cardiovascular Medicine.
Prof. Elgebaly founded Nour Heart, Inc. in 2006 to pursue research into heart-related diagnostic and therapeutic products and is a Professor at the University of Connecticut Faculty of Medicine (Adj.), Farmington, Connecticut, U.S.



Introducing Prof. Dr. Salwa Ahmed Elgebaly

- CEO, Nour Heart, Inc. Established in Hartford, Connecticut, USA
- Professor, University of Connecticut Faculty of Medicine (Adj.), Farmington, Connecticut, USA

The aim of Nour Heart is to develop Cyclocreatine Phosphate as a new cardioprotective drug for patients with ischemic heart disease.
She is the Inventor of nine (9) Patents Issued by the U.S. Patent Office and two pending applications.

In 2005, Dr. Elgebaly initiated and was instrumental in implementing the establishment of the first Clinical Research Center (CRC) at Alexandria Faculty of Medicine to conduct all phases of FDA-regulated clinical trials. The CRC celebrated its tenth year in 2016 as the best in Egypt and Middle East according to international pharmaceutical companies. Dr. Elgebaly serves as a volunteer Consultant in the CRC.